Study of the Immune Response in Colon Adenocarcinoma (IMCO)

I

Institut National de la Santé Et de la Recherche Médicale, France

Status

Active, not recruiting

Conditions

Colon Adenocarcinoma

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03015038
2016-A01102-49 (Other Identifier)
C16-21

Details and patient eligibility

About

Duration of each part of the study per patient: Screening: From 1 to 4 weeks Sampling period (blood and tissue): 1 day Follow-up by patient: 60 months Total study duration by patient: 84 months Total inclusion duration: 24 months Total Follow-up duration: 60 months Total study duration: 84 months

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged 18 or more.
  • Affiliation to a social security scheme
  • Diagnosis of a colon adenocarcinoma.
  • Patient have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion criteria

Patients under guardianship / curatorship

Following Situations

  • Persons unable to understand, read and / or sign an informed consent
  • Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study
  • Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year.
  • No affiliation to a social security scheme, a universal medical coverage or any similar plan.
  • Pregnant or lactating women.
  • Patients with HIV seropositivity.
  • Rectal tumor location.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems